On March 8, 2019, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Tecentriq (atezolizumab). This approval, sponsored by Genentech Inc., specifically pertains to the drug's demonstrated efficacy, indicating an expansion or modification of its approved uses.
Background
Atezolizumab, marketed as Tecentriq, is an established therapeutic agent. Supplemental applications to the FDA are a standard regulatory mechanism for drug manufacturers to update or expand a drug's approved labeling. These applications can cover new indications, patient populations, dosing regimens, or other changes based on new clinical data. An approval for efficacy, as was the case here, confirms that new data supports the drug's effectiveness for an additional or modified use.
What this means
The FDA's approval of a supplemental application for Tecentriq (atezolizumab) for efficacy means that the drug has met regulatory standards for demonstrating effectiveness in an expanded or refined context. While the specific details of the new indication or patient population are not provided in the source data, this type of approval typically leads to updates in the drug's prescribing information. Clinicians should consult the updated label for Tecentriq to understand the full scope of this new approval and its implications for patient care.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval was issued on March 8, 2019, and details are accessible via the FDA's website, specifically referencing BLA 761034 S-18 on accessdata.fda.gov.